Arcus Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Arcus Biosciences, Inc. on March 25, 2019. The filing discloses the appointment of a new senior executive officer effective as of the report date.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation and appointment details.
Material Changes
The primary material change reported is the appointment of Rekha Hemrajani as Chief Operating and Financial Officer. In this capacity, she will serve as the Company's principal financial and accounting officer.
Compensation and Appointment Details
- Base Salary: $425,000 annually.
- Sign-on Bonus: One-time payment of $200,000.
- Target Bonus: 40% of base salary annually.
- Equity Grant: Option to acquire 400,000 shares of common stock under the 2018 Equity Incentive Plan.
- Vesting Schedule: Monthly vesting over four years, subject to continued service.
- Change in Control: Options subject to accelerated vesting upon a Change in Control.
Management Commentary and Background
Ms. Hemrajani joins Arcus from FLX Bio, where she served as Chief Operating Officer from March 2016 to March 2019. Her prior experience includes roles as CFO at 3-V Biosciences and leadership positions in business development and M&A at Onyx Pharmaceuticals and Exelixis. She holds a B.S. from the University of Michigan and an M.B.A. from Northwestern University's Kellogg Graduate School of Management.
Investor Verification Checklist
- Verify the total cash compensation package ($425,000 base + $200,000 bonus) against the company's current cash position.
- Confirm the fair market value of the stock on the grant date to calculate the exercise price for the 400,000 share option.
- Review the previously filed Severance and Change in Control Agreement to understand the specific triggers for accelerated vesting.
- Assess the impact of the new CFO appointment on the company's financial reporting and strategic direction.